Dr. Benjamin Musher wird Leiter der Phase-I/II-Studie zur Beurteilung von Natrunix™, der Anti-Tumor-Therapie von XBiotech bei Bauchspeicheldrüsenkrebs

Matthew Durham
Omnidynamic Marketing

Liz Kane
Impactful Strategy

Suma Ramadas, PhD
Medical Affairs

Brenda Snow
Authentic Patient Voice

Stacey Gandler
Brand Nourishment

Daniel Sontupe
Market Access

David Linetsky
Point-of-Care Marketing

Frank Burrell
Scientific Storytelling

Pat Purcell
Meeting Engagement

Bud Bilanich
Success Coach

Joey Cohen
Medication Adherence

Matt Turner
Patient Affordability

Amy Giles
Increasing Engagement

Paul Theisen
Patient Acquisition